Comprehensive and fully integrated platform for mRNA vaccine and therapy, accelerating the development of life-saving treatments.
Our mRNA facility is equipped with advanced technology and processes to ensure efficient, high-quality production of mRNA therapeutics and vaccines. It consists of more than 30,000 square feet of laboratory and GMP manufacturing. It supports the production of non-GMP products for formulation development and toxicology studies, as well as GMP products for early and late-stage clinical trials. Operations commenced in 2021.
We manufacture a comprehensive range of raw materials in-house, including nucleosides, nucleotides, modified nucleotides, enzymes, cap analogues, and lipids, allowing researchers and manufacturers to focus on their mRNA development efforts without having to worry about sourcing quality materials.
An experienced team with a proven track record in working with different types of RNA, including conventional mRNA, self-amplifying mRNA, and circular RNA, offers customers various platforms.
